Author

I. Yeh

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Research Focus:variant calling· 2 Assay:whole-exome sequencing· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

B. C. Bastian· 4 shared A. H. Shain· 2 shared M. Wang· 2 shared A. B. Olshen· 1 shared A. Goel· 1 shared A. M. Wolff· 1 shared A. Oh· 1 shared A. Renslo· 1 shared

Activity by Year

2018-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

B. C. Bastian

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

The genetic evolution of acral melanoma

M. Wang, S. Fukushima, Y.-S. Sheen, E. Ramelyte, N. Cruz Pacheco, C. Shi, S. Liu, I. Banik, J. D. Aquino, M. Sangueza Acosta, M. Levesque, R. Dummer, J.-Y. Liau, C.-Y. Chu, A. H. Shain, , B. C. Bastian

This study analyzes exome sequencing data from acral melanoma patients to identify distinct genetic evolution patterns compared to sun-exposed melanomas.

bioRxiv · Oct 18, 2023Cancer Biology

Distinct senescence mechanisms restrain progression of dysplastic nevi

F. K. Lorbeer, G. Rieser, A. Goel, M. Wang, A. Oh, I. Yeh, B. C. Bastian, D. Hockemeyer

The paper investigates the role of TERT promoter mutations in dysplastic nevi and their association with senescence mechanisms and progression to melanoma.

bioRxiv · Jul 14, 2023Cancer Biology

Exploiting KRAS-driven Ferroaddiction in Cancer Through Ferrous Iron-Activatable Drug Conjugates (FeADC)

H. Jiang, R. K. Muir, R. L. Gonciarz, A. B. Olshen, I. Yeh, B. C. Hann, N. Zhao, Y.-h. Wang, J. Korkola, S. C. Behr, M. J. Evans, e. collisson, A. Renslo

This paper develops FeADCs, ferrous iron-activatable drug conjugates, to target KRAS-driven cancers with improved tumor selectivity and systemic tolerability.

bioRxiv · May 12, 2020Cancer Biology

Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation positive lung cancer

J. K. Rotow, P. Gui, W. Wu, V. M. Raymond, R. B. Lanman, F. J. Kaye, N. Peled, F. Fece de la Cruz, B. Nadres, R. B. Corcoran, I. Yeh, B. C. Bastian, P. Starostik, K. Newsom, V. R. Olivas, , C. M. Blakely

The paper identifies co-occurring RAS-MAPK pathway alterations in MET exon 14 skipping mutation positive lung cancers that limit response to MET inhibitors and suggests combining MET and MEK inhibitors to overcome resistance.

bioRxiv · May 24, 2019Cancer Biology

A machine-learning classifier trained with microRNA ratios to distinguish melanomas from nevi

R. Torres, U. E. Lang, M. Hejna, S. J. Shelton, N. M. Joseph, A. H. Shain, I. Yeh, M. L. Wei, M. C. Oldham, B. C. Bastian, R. L. Judson-Torres

This study develops a machine learning classifier using microRNA ratios to distinguish melanomas from nevi, achieving 83% sensitivity and 71-83% specificity across multiple datasets.

bioRxiv · Dec 27, 2018 · PreprintCancer Biology